CNS Pharmaceuticals (CNSP) SEC Filings & 10K Form $6.21 -0.06 (-0.96%) As of 12:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent CNS Pharmaceuticals SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel DateFilerForm TypeView08/14/20257:56 PMARMISTICE CAPITAL, LLC (Filed by)CNS Pharmaceuticals (Subject)Form SCHEDULE 13G07/15/20254:19 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/14/20257:59 AMCNS Pharmaceuticals (Filer)Form 424B405/13/202511:15 PMCNS Pharmaceuticals (Filer)Form EFFECT05/12/20255:03 AMCNS Pharmaceuticals (Filer)Form S-1/A04/09/20252:32 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 03/31/20254:11 PMCNS Pharmaceuticals (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 03/31/20254:12 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 03/20/20254:17 PMCNS Pharmaceuticals (Filer)Form 424B503/20/20254:15 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/21/20254:00 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 12/11/202411:24 AMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/15/20243:19 PMCNS Pharmaceuticals (Filer)Form DEFR14A11/01/20248:00 AMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 10/28/20243:15 PMCNS Pharmaceuticals (Filer)Form DEF 14A10/24/20244:27 PMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 10/24/202410:23 AMCNS Pharmaceuticals (Filer)Form 424B510/23/20247:02 AMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 10/15/20244:24 PMCNS Pharmaceuticals (Filer)Form PRE 14A09/12/20247:58 AMCNS Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Soligenix 10K Form Aptorum Group 10K Form Allarity Therapeutics 10K Form NextCure 10K Form ProPhase Labs 10K Form Neuphoria Therapeutics 10K Form Bullfrog AI 10K Form TherapeuticsMD 10K Form AlloVir 10K Form Leap Therapeutics 10K Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:CNSP) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access